FDA clears Hemagen's clinical chemistry reagents:
This article was originally published in Clinica
Hemagen Diagnostics has received US FDA 510(k) clearance to market four of its clinical chemistry reagents - total protein, albumin, calcium and GGT (gamma-glutamyl transferase)- may be use on Roche Diagnostics' Cobas Mira analyser. Waltham, Massachusetts-based Hemagen announced last month that it had entered into a long-term agreement to provide reagents and diagnostic kits manufactured by its Raichem division to Roche Diagnostics (see Clinica No 894, p 10). Hemagen said the newly cleared reagents marked the first of a number of clearances under the agreement and that it was working on further 510 (k) submissions for other products.
You may also be interested in...
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.